FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026GlobeNewsWire · 2 days ago
FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 1, 2026
Analysts Set FocalTherics (NASDAQ:FOCL) Target Price at $9.00Defense World · Aug 17, 2026
EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 13, 2026
FocalTherics Q2 Earnings Call HighlightsMarketBeat · Aug 13, 2026
FocalTherics™ Reports Second Quarter 2026 Financial ResultsGlobeNewsWire · Aug 13, 2026EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.20 | -$0.39 | Miss |
| May 7, 2026 | -$0.20 | -$0.24 | Miss |
| Mar 25, 2026 | -$0.15 | -$0.25 | Miss |
| Nov 6, 2025 | -$0.25 | -$0.15 | Beat |
| Aug 28, 2025 | -$0.21 | -$0.18 | Beat |
| May 15, 2025 | -$0.16 | -$0.21 | Miss |